Previous 10 | Next 10 |
Revelation Biosciences Inc. (REVB) is expected to report $-0.3 for Q3 2023
- Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study - Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company’s Gemini formulation de...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke wil...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to ...
2023-08-11 16:36:24 ET Revelation Biosciences press release ( NASDAQ: REVB ): Q2 GAAP EPS of -$0.25. As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivale...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 202...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meetin...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 An...
2023-05-22 09:44:29 ET Revelation Biosciences press release ( NASDAQ: REVB ): Q1 GAAP EPS of $1.96. As of March 31, 2023, Revelation had $17.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. For further details see: Revelat...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 finan...
News, Short Squeeze, Breakout and More Instantly...
Revelation Biosciences Inc. Company Name:
REVB Stock Symbol:
OTCMKTS Market:
Revelation Biosciences Inc. Website:
2024-06-25 06:18:00 ET 3 Ways That the 2024 Election Can Impact Penny Stocks Elections can significantly influence financial markets, including the domain of penny stocks . Penny stocks, often traded below five dollars per share, present a unique opportunity for investors aiming for...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced ...